This site uses cookies to provide you with a great user experience. By using BondbloX, you accept our use of cookies.
Bond Market News
Merck Said to be Close to a $6bn Cash Acquisition for Terns Pharma
March 26, 2026
American pharmaceutical company Merck is said to be close to a $6bn all-cash deal to acquire clinical-stage biopharmaceutical company Terns Pharma, as per FT citing sources. The potential acquisition comes on the back of Merck working towards reshaping its oncology strategy. Besides, Merck is also believed to be in the process of establishing a dedicated cancer division centered around its drug Keytruda, preparing for the drug’s patent expiration in 2028. While both companies did not respond to comments, sources note that negotiations are at an advanced stage.
Merck’s bonds were trading stable, with its 4.75% 2035s at 97.8 cents on the dollar, yielding 5%.
For more details, click here
Go back to Latest bond Market News
Related Posts:
Sinopec Returns to the Dollar Bond Market for a Second Time in 2017
September 13, 2017
S&P Upgrades Yanlord by One Notch to ‘BB’
March 16, 2018
BondbloX Pte. Ltd. is regulated by the Monetary Authority of Singapore as a Recognised Market Operator ("RMO") and exempted from Section 49(1) of the Securities and Futures Act (Cap. 289) ("SFA") under Section 49(7) of the SFA.